Lymphoscintigraphy and sentinel nodes.

Area of Science:

• Oncology
• Surgical Pathology
• Cancer Staging

Background:

• Sentinel lymph node biopsy (SLNB) has transformed the management of breast cancer and melanoma.
• It is now the preferred staging method for early-stage disease, replacing more invasive procedures when metastases are absent.

Purpose of the Study:

• To evaluate the efficacy and impact of SLNB on patient survival and morbidity in breast cancer and melanoma.
• To compare SLNB outcomes with traditional lymph node dissection methods.

Main Methods:

• Analysis of multicenter, randomized trials for breast cancer with 5- to 10-year outcome data.
• Review of the Multicenter Selective Lymphadenectomy Trial I for melanoma survival impact.
• Utilized preoperative lymphoscintigraphy and dual mapping for lowest false-negative rates.

Main Results:

• For breast cancer, SLNB showed no significant difference in disease-free or overall survival compared to axillary lymph node dissection (ALND), but with significantly lower morbidity.
• In melanoma, SLNB did not alter melanoma-specific survival but improved 10-year disease-free survival, particularly for intermediate and thick melanomas.

Conclusions:

• SLNB is a safe and effective staging modality for breast cancer and melanoma, offering reduced morbidity.
• SLNB provides comparable survival outcomes to traditional dissections while minimizing patient complications.